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Median Pre
CD34 /uL
Median CD34/ kg
Initial Collection
Median CD34/ kg
Second Collection
Median % of
Initial Collection
Days to ANC
>0.5 x109/L
Days to Plt
>50 x109/L
NHL (n¼7) 2.1 (1.5-6.2) 1.5 (1.27-1.68) 0.68 (0.27-1.96) 41% (21-114) 11 (10-12) 16 (11->28)
MM (n¼3) 3.1 (3.1-5.7) 3.01 (1.85-3.77) 1.51 (1.11-3.01) 60% (40-85) 11 (9-12) 14 (13-14)
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high cost of P and the inability to determine which patients
will collect poorly using clinical parameters alone.
Previous studies have shown that the high cost of P is
justiﬁed based on fewer apheresis days required. However
when patients require 2 or more days of P the costs can
become prohibitive.
To alleviate the need for additional days of P we piloted an
approach where patients who were close to achieving their
target collection goal after the ﬁrst day of P continued their G
CSF, but without an additional dose of P. Minimum accepted
collection goals were 2 x 106 CD34/kg for NHL patients and 4
x 106CD34/kg for MM patients.
From April 2012 through April 2014 170 patients underwent
an autologous transplant. Fifty (29.4%) ultimately required P
to mobilize adequate numbers of cells. Ten patients (7 NHL, 3
MM) were judged close to their preset target collection goal
after their ﬁrst dose of P. These patients were collected the
following day without an additional dose of P.
As shown in Table 1 the median peripheral blood CD34/uL
count prior to collection was 2.1 for NHL and 3.1 for MM. The
median CD34 x 106/kg collected the day following the dose of
P was 1.5 (NHL) and 3.01 (MM). On the second day of
collection without P, the median CD34 x 106collected was
0.68 (NHL) and 1.51 (MM). All patients achieved their target
goals and were able to successfully proceed to trans-
plantation. The median percentage of the original collection
is 40 and 60% respectively for NHL and MM. All patients
engrafted with similar times to patients not requiring P, or
who had a successful collection with a single apheresis.
It appears that in patients who are close to achieving their
target dose, that the strategy of omitting the second dose of P
can successfully allow collection of sufﬁcient cells to permit
autologous transplant with appropriate engraftment times.
In our population 20% of the patients who received P fell into
this category.With a cost of approximately $7000 per patient
dose, the cost savings per 100 patients transplanted would
be approximately $42,000. Such an approach clearly
can minimize the costs associated with stem cell
mobilization and collection without any difference in the
clinical outcome.363
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Ambisome (amphotericin B liposomal complex, L-Amb) is
highly effective for the treatment of invasive fungal
infections (IFI) and may be an important prophylactic drug in
patients undergoing hematopoietic stem cell transplant(HSCT). Several new anti-fungal drugs have become available
over the past few years leading to various prospective studies
aiming to assess the role of prophylaxis and treatment in IFI
in HSCT. But drug related factors such as safety, efﬁcacy,
toxicity proﬁle in the setting of pre-existing organ dysfunc-
tion and potential drug interaction, need to be considered.
Ambisome is a liposomal formulation containing ampho-
tericin B and is comparatively found to cause fewer infu-
sional reactions and achieve superior plasma and tissue
concentrations.
To determine the optimal approach for prophylactic
antifungal therapy, we prospectively analyzed the efﬁcacy
and safety of low dose Ambisome, which is 1mg per kg
body weight on alternate days in nineteen patients who
underwent hematopoietic stem cell transplant at our insti-
tute, for the prophylaxis of IFI. This was a heterogeneous
study group, having varied indications for transplant.
Results: The low dose regimen of 1mg/kg body weight on
alternate days was well tolerated. Four out of nineteen
patients developed manageable hypokalemia. No renal
toxicity or infusional reactions were documented. However,
a test dosewas always administered. Only one patient having
a T replete haploidentical transplant for follicular lymphoma
developed probable IFI requiring anti-fungal therapy.
Conclusion: We conclude that low dose L-Amb may provide
useful protection against invasive fungal infections in
patients undergoing hematopoietic stem cell transplant.364
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Respiratory and skeletal muscle strength and submaximal
exercise capacity and physical activity levels are known to be
reduced in a signiﬁcant percentage of patients prior to
hematopoietic stem cell transplantation (HSCT). However,
determinants of physical activity levels of HSCT recipients
have not been investigated so far. The aim of this study was
to determine the role of physical activity levels in HSCT
recipients.
Patients and Methods: This prospective cross sectional
study included 36 HSCT recipients. Physical activity levels
were assessed using a multisensory armband device and
pulmonary function tests. Functional exercise capacity was
evaluated with 6-minute walking test (6MWT), respiratory
muscle strength (MIP, MEP) with mouth pressure device,
peripheral muscles strength with dynamometer, and
dyspnea with Modiﬁed Medical Research Council
(MMRC) dyspnea scale. Correlations of exercise capacity
parameters were done with the grade of cardiac and
pulmonary toxicity, febrile neutropenia, and transplant
related mortality (TRM).
Results: All HSCT recipients were inactive (<3.0 METs)
according to daily average METs (1.260.18 METs) and
